Abstract: A 1,4-polyisoprene dispersion system is selected from a 1,4-polyisoprene solution dispersion system and a 1,4-polyisoprene emulsion dispersion system. The 1,4-polyisoprene solution dispersion system includes 1,4-polyisoprene and a solvent. The 1,4-polyisoprene emulsion dispersion system includes 1,4-polyisoprene, an emulsifier, and water.

Abstract: Anthraquinone analogs that have anticancer properties are disclosed. Pharmaceutical formulations in forms suitable for the delivery of the compounds to a subject in need thereof are disclosed. Methods of using the compounds for treating or ameliorating one or more symptoms associated with a cancer, such as leukemia, in a subject are also disclosed. The methods include (i) administering to the subject the pharmaceutical formulation containing one or more compounds, for one or more times. The compounds can induce apoptosis in cancer cells, such as leukemia cells harboring WT-p53 (e.g., EU-1 leukemia cells), MCF7 cells, RS4;11 cells, and/or HeLa cells, by downregulating MDM2 and upregulating p53 in these cancer cells.

Abstract: Provided is a dynamic time warping (DTW)-based real-time diagnosis method for a commutation failure (CF). The method includes: designing a time series template S0 containing a change of a firing angle of a phase-controlled rectifier, and having a length n and a Euclidean distance L; using an n*n matrix M to represent a Euclidean distance between each point in the S0 and each point in the Si, and constricting the matrix M with an Itakura window; calculating values of the matrix M in the search range H; setting different weights for data at different locations, and searching a shortest path L* from point (x1, y1) to point (xn, yn) of the matrix; and setting a range of the distance L of the S0 as ?, determining that the CF fault occurs if the L* is greater than ?L, or otherwise, determining that a system works normally.

Abstract: New derivatives of human milk oligosaccharides and methods for preparing them are disclosed. Also described herein are hST6GALNAC V and hGCNT2-B variants, along with polynucleotides encoding the variants and host cells comprising the polynucleotides. Further provided herein are reaction mixtures comprising the hST6GALNAC V and hGCNT2-B variants.

Abstract: Novel rhodanine derivatives and methods for their use are provided herein. The rhodanine derivatives are useful in treating or preventing viral infections, including coronavirus infections (e.g., a SARS-CoV-2 virus infection). The rhodanine derivatives are also useful as photosensitizers for photodynamic therapy in treating or preventing cancer in a subject.

Abstract: The present invention provides new compounds and compositions thereof that release carbon monoxide for the treatment of medical disorders that are responsive to carbon monoxide, for example, inflammatory, pain, and dermatological disorders.

Abstract: The present invention provides new compounds and compositions thereof that release carbon monoxide for the treatment of medical disorders that are responsive to carbon monoxide, for example, inflammatory, pain, and dermatological disorders.

Abstract: The present invention relates to a medicine for treating disorders of glucose and/or lipid metabolism. This invention demonstrates a new therapeutic target for treatment of glucose and/or lipid metabolic disorders. The invention further provides a method of treating glucose and/or lipid metabolic disorders, administering to a subject comprising a Nogo-B inhibitor, thereby treating the glucose and/or lipid metabolic disorders.

Abstract: The present invention provides new compounds and compositions thereof that release carbon monoxide for the treatment of medical disorders that are responsive to carbon monoxide, for example, inflammatory, pain, and dermatological disorders.

Abstract: The present invention relates to a medicine for treating disorders of glucose and/or lipid metabolism. This invention demonstrates a new therapeutic target for treatment of glucose and/or lipid metabolic disorders. The invention further provides a method of treating glucose and/or lipid metabolic disorders, administering to a subject comprising a Nogo-B inhibitor, thereby treating the glucose and/or lipid metabolic disorders.